Verinata Health, Inc. (Verinata), a privately-held company, is driven by a sole and extraordinary purpose — maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities through our proprietary technologies.
We aim to reduce the anxiety associated with today’s multi-step process, the unacceptable false positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures.
In support of national guidelines recommending first trimester aneuploidy risk assessment we believe women who desire such a risk assessment should be offered a single blood draw test with a definitive result.
As its first product Verinata is proud to offer the verifi® prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks.
In addition, Verinata now offers the Monosomy X option, a test for Turner syndrome, as an optional addition to the verifi® prenatal test. The Monosomy X option may be ordered for patients with cystic hygroma, an ultrasound finding which suggests that the fetus has an increased risk of having an abnormal number of chromosomes. The verifi test is available for all pregnant women determined to be high risk by their physician.
Verinata Health is excited to be at the forefront of improving prenatal testing options and is committed to helping clinicians offer the latest in prenatal care to patients.